Loading
A phase 1/2 trial of Obinutuzumab, Glofitamab, Rituximab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05533775 by Hoffmann-La Roche, with 65 participants planned, started 2022-11-16 and due to reach its primary completion in 2029-11-30. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin. Conditions listed: Mature B-Cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares Ifosfamide, Etoposide, Rituximab, T-cell engagers (bispecific).
Shares Glofitamab, Obinutuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Glofitamab, Obinutuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Glofitamab, Obinutuzumab, Rituximab, Hodgkin lymphoma.
Shares Glofitamab, Obinutuzumab, Rituximab, T-cell engagers (bispecific).
Shares Ifosfamide, Etoposide, Rituximab, Non-Hodgkin lymphoma (all types).
Shares Glofitamab, Obinutuzumab, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares Rituximab, Roche / Genentech, T-cell engagers (bispecific), Hodgkin lymphoma.